Which programmed death receptor-1 blocking antibody drugs treat urinary bladder neoplasms?

pharmaranks lists 2 Programmed Death Receptor-1 Blocking Antibody products used for urinary bladder neoplasms, per NIH RxClass drug-classification data — each independently rated and ranked above.

How are these ranked?

By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.

Best Programmed Death Receptor-1 Blocking Antibody for urinary bladder neoplasms

Top-rated pick: Opdivo — pharmaranks score 72/100, the highest of the 2 Programmed Death Receptor-1 Blocking Antibody drugs used for urinary bladder neoplasms, ranked by our independent FDA recall-safety score. Compare them with all treatments for urinary bladder neoplasms or the full Programmed Death Receptor-1 Blocking Antibody class. Not medical advice — always consult a professional.

Quick answer: Of the 2 programmed death receptor-1 blocking antibody drugs we rate for urinary bladder neoplasms, none are yet flagged as generics in our price data, and most are injectable. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for urinary bladder neoplasms; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Other drug classes for urinary bladder neoplasms

Best alkylating drug Best platinum-based drug Best topoisomerase inhibitor Best anthracycline topoisomerase inhibitor

Top programmed death receptor-1 blocking antibody for urinary bladder neoplasms: 1. Opdivo · 2. Keytruda

Best-rated Programmed Death Receptor-1 Blocking Antibody for urinary bladder neoplasms, ranked by pharmaranks score
#	Drug	Rating	Type	Form	Generic?	Pharmacy pays
1	Opdivo	72/100	Prescription	Injectable	No data	—	View →
2	Keytruda	70/100	Prescription	Injectable	No data	—	View →

Full ranking · 2 drugs

opdivo

PrescriptionFDA-sourced

72/100

Opdivo (Nivolumab) is a programmed death receptor-1 blocking antibody used to treat Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma, Kidney Neoplasms.

(4 data points)

programmed death receptor-1 blocking antibodyurinary bladder neoplasmscarcinoma, non-small-cell lung

Price varies

View details →

keytruda

PrescriptionFDA-sourced

70/100

Keytruda (Pembrolizumab) is a programmed death receptor-1 blocking antibody used to treat Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma.

(3 data points)

programmed death receptor-1 blocking antibodymesothelioma, malignantbiliary tract neoplasms

Price varies

View details →

Frequently asked

What is the best programmed death receptor-1 blocking antibody for urinary bladder neoplasms?: By our independent recall-safety rating — not an efficacy measure — opdivo ranks highest among Programmed Death Receptor-1 Blocking Antibody drugs used for urinary bladder neoplasms. Always consult a professional.
Which programmed death receptor-1 blocking antibody drugs treat urinary bladder neoplasms?: pharmaranks lists 2 Programmed Death Receptor-1 Blocking Antibody products used for urinary bladder neoplasms, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?: By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.